RxDoctor Payments DataLook up a doctor →

Amy Shaver

Acute Care · North Chesterfield, VANPI 1134545239

Payments from drug & device makers

$7,629in general payments, 2019–2025

Across 339 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$787
  • AstraZeneca$763
  • Incyte Corporation$448
  • Johnson & Johnson$350
  • Genentech USA, Inc.$294
  • Astellas Pharma US Inc$284
  • plus $5K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis36$787
AstraZeneca34$763
Incyte Corporation17$448
Johnson & Johnson23$350
Genentech USA, Inc.11$294
Astellas Pharma US Inc10$284
Pfizer13$258
Eisai Inc.13$258
Merck13$254
Amgen8$233
Ipsen Biopharmaceuticals, Inc8$189
Sanofi-aventis U.S. LLC2$182
Daiichi Sankyo Inc.8$163
EMD Serono, Inc.8$161
Bayer7$161
Sanofi7$153
Karyopharm Therapeutics Inc.7$152
AbbVie6$125
Regeneron Healthcare Solutions, Inc.6$124
Exelixis Inc.2$121
Taiho Oncology, Inc.5$113
Legend Biotech USA Inc.5$110
Collegium Pharmaceutical, Inc.2$109
Takeda Pharmaceuticals U.S.A., Inc.5$109
Gilead(2 entities)3$79
Beone Medicines USA, Inc.3$79
Rigel Pharmaceuticals, Inc.4$78
Seagen Inc.4$77
Pharmacyclics LLC, An Abbvie Company4$77
E.r. Squibb & Sons, L.L.C.4$69
Pharmacosmos Therapeutics Inc.3$67
Lilly USA, LLC3$65
Mirati Therapeutics, Inc.3$64
Sobi, Inc3$62
ADC Therapeutics America, Inc.4$62
Caris MPI, Inc.3$60
Array Biopharma Inc3$60
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$54
Tersera Therapeutics LLC2$54
Stemline Therapeutics Inc.2$52
Servier Pharmaceuticals LLC3$49
Azurity Pharmaceuticals, Inc.2$48
GRT US Holding, Inc.1$45
Kyowa Kirin, Inc.2$42
Adaptive Biotechnologies Corporation2$41
Bristol Myers Squibb2$40
G1 Therapeutics, Inc.2$40
Boehringer Ingelheim2$33
AVEO Pharmaceuticals, Inc.2$32
Genmab U.S., Inc.2$32
Celltrion USA Inc.1$26
GSK1$26
Geron Corporation1$25
Impel Pharmaceuticals Inc.1$23
Jazz Pharmaceuticals Inc.1$21
Beigene USA, Inc.1$20
Morphosys, US Inc.1$19
Coherus Oncology, Inc.1$18
Novocure Inc.1$17
Iovance Biotherapeutics, Inc.1$16

How this compares

$7,629 in reported general payments places this provider in the 95th percentile of 599 acute care providers in Virginia.

See all acute care providers in Virginia →

Medicare billing

Part B allowed, 2024
$32,039
Medicare patients
132
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in North Chesterfield

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →